-
公开(公告)号:RU2002123369A
公开(公告)日:2004-01-10
申请号:RU2002123369
申请日:2001-02-01
IPC: A61K31/663 , A61K31/675 , A61P3/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , C07D201/00 , C07F9/58
-
公开(公告)号:DE69719042T2
公开(公告)日:2003-11-27
申请号:DE69719042
申请日:1997-08-28
Inventor: GUIT PHILIPPUS , BUIJS WIM
IPC: C07D201/00 , C07D201/08
-
公开(公告)号:DK1140935T3
公开(公告)日:2003-09-01
申请号:DK99969220
申请日:1999-12-17
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANGIBAUD PATRICK RENE , VENET MARC GASTON , BOURDREZ XAVIER MARC
IPC: C07D215/06 , A61K31/4365 , A61K31/4709 , A61K31/4745 , A61K31/498 , A61K31/519 , A61P35/00 , C07D215/18 , C07D401/06 , C07D403/06 , C07D471/04 , C07D487/04 , C07D201/00
Abstract: This invention concerns compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein -X 1 -X 2 -X 3 - is a trivalent radical,; >Y 1 -Y 2 - is a trivalent radical; r and s are each independently 0, 1, 2, 3, 4 or 5; t is 0, 1, 2 or 3; each R 1 and R 2 are independently hydroxy, halo, cyano, C 1-6 alkyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxyC 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, aminoC 1-6 alkyloxy, mono- or di(C 1-6 alkyl)amino, mono- or di(C 1-6 alkylaminoC 1-6 alkyloxy, aryl, arylC 1-6 alkyl, aryloxy or arylC 1-6 alkyloxy, hydroxycarbonyl, C 1-6 alkyloxycarbonyl; or two R 1 or R 2 on adjacent positions form together a bivalent radical; R 3 is hydrogen, halo, C 1-6 alkyl, cyano, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, cyanoC 1-6 alkyl, aminoC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, C 1-6 alkylthio-C 1-6 alkyl, aminocarbonylC 1-6 alkyl, hydroxycarbonyl, hydroxycarbonylC 1-6 alkyl, C 1-6 alkyoxycarbonylC 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkyloxycarbonyl, aryl, arylC 1-6 alkyloxyC 1-6 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, or a radical of formula -O-R 10 , -S-R 10 or -NR 11 R 12 ; R 4 is an optionally substituted imidazolyl; aryl is an optionally substituted phenyl or naphthalenyl; having farnesyl transferase and geranylgeranyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:PE20030712A1
公开(公告)日:2003-08-21
申请号:PE2002001102
申请日:2002-11-14
Applicant: SQUIBB BRISTOL MYERS CO
Inventor: MASTALERZ HAROLD , TARRANT JAMES G , VITE GREGORY D , ZHANG GUIFEN
IPC: A61K31/53 , A61K31/5377 , A61K45/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D201/00 , C07D487/04
Abstract: SE REFIERE A DERIVADOS DE INDAZOLILPIRROLOTRIAZINAS C-5 MODIFICADAS, DE FORMULA I SUS ENANTIOMEROS, DIASTEREOMEROS, SALES DONDE R ES SR2, SOR2, OR2, NR3R4; R1 ES ARILO, HETEROCICLO, ENTRE OTROS; R2 ES H, ALQUILO, ARILO, ARALQUILO, HETEROCICLO; R3 Y R4 SON H, ALQUILO, ARILO, HETEROCICLO; R2 Y R3 JUNTOS FORMAN UN ANILLO CARBOCICLO, HETEROCICLO. SON COMPUESTOS PREFERIDOS (5-[1,4]DIAZEPAN-1-ILMETIL-PIRROLO[2,1-f][1,2,4]TRIAZIN-4-IL)-[1-(3-FLUOR-BENCIL)-1H-INDAZOL-5-IL]-AMINA, [1-(3-FLUOR-BENCIL)-1H-INDAZOL-5-IL]-(5-IMIDAZOL-1-ILMETIL-PIRROLO[2,1-f][1,2,4]TRIAZIN-5-ILMETIL}-PIPERIDIN-3-CARBOXILICO, AMIDA DEL ACIDO 1-{4-[1-(3-FLUORO-BENCIL)-1H-INDAZOL-5-ILAMINO]-PIRROLO[2,1-f][1,2,4]TRIAZIN-5-ILMETIL}-PIPERIDIN-3-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS INHIBEN LA ACTIVIDAD DE LA TIROSINA CINASA DE LOS RECEPTORES DEL FACTOR DE CRECIMIENTO TALES COMO HER1, HER2, HER4 Y SON UTILES COMO AGENTES ANTIPROLIFERATIVOS
-
公开(公告)号:HK1051046A1
公开(公告)日:2003-07-18
申请号:HK03101833
申请日:2003-03-13
Applicant: PROCTER & GAMBLE
Inventor: CAZER FREDERICK DANA , PERRY GREGORY EUGENE , BILLINGS DENNIS MICHAEL , REDMAN-FUREY NANCY LEE
IPC: A61K31/663 , A61K31/675 , A61P3/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , C07D201/00 , C07F9/58 , C07F , A61K , A61P
Abstract: The present invention discloses 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium hemipentahydrate and monohydrate, methods of preparing the hemipentahydrate or monohydrate through control of the nucleation temperature and rate of crystallization and pharmaceutical compositions containing one or both of the hydrate forms.
-
公开(公告)号:DE10256354A1
公开(公告)日:2003-06-18
申请号:DE10256354
申请日:2002-12-03
Applicant: SYNGENTA PARTICIPATIONS AG
Inventor: EDMUNDS ANDREW , SCHAETZER JUERGEN , LUETHY CHRISTOPH , DIGGELMANN MARTIN
IPC: A01N43/40 , C07D213/50 , C07D213/57 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D201/00
Abstract: 5-substituted thiol-4-(pyridinylcarbonyl)-cyclohexene-1,3-dione derivatives (I) and their salts, all isomers and tautomers are new. 5-substituted thiol- 4-(pyridinylcarbonyl)-cyclohexene-1,3-dione derivatives of formula (I) and their salts, all isomers and tautomers are new. R = 1-12C alkyl, 2-12C alkenyl or alkynyl, 3-12C allenyl, 3-12C cycloalkyl, 5-12C cycloalkenyl, R1-(1-12C alkylene or 2-12C alkenylene) (where alkylene and alkenylene may be interrupted by oxygen, S(O)p, or CO and substituted by one or more R2, or phenyl (optionally substituted 1-5 times by R11)), 3-12 membered aromatic or partially or fully saturated mono- or bi-cyclic ring system, (optionally containing 1-5 heteroatoms (nitrogen, oxygen and/or sulfur)) or 1-2 carbonyl (optionally substituted by one or more R3), with the ring system attached, via C or N atoms, directly or through a 1-6C alkylene or alkenylene linker (optionally interrupted by O or S(O)p and/or substituted by R4) to the S of S(O)nR, and substituents on N are other than halo, or halo, 1-12C alkylthio, cyano, C(X1)R6, C(X2)X3R7, C(X4)NR8R9, or, if n = 0, also hydrogen, cyano or isocyano or hydroxy, or NR80R90 when n = 1 or 2; Z1 = 1-3C alkyl; Y = hydrogen, chloro, bromo or 1-2C (halo)alkyl; n and p = 0-2; q = 0 or 1; and X1-X4 = oxygen or sulfur; The full definitions are given in the DEFINITIONS (Full Definitions) Field. An Independent claim is also included for the preparation of (I).
-
公开(公告)号:IL150511D0
公开(公告)日:2003-02-12
申请号:IL15051101
申请日:2001-02-01
Applicant: PROCTER & GAMBLE
IPC: A61K31/663 , A61K31/675 , A61P3/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , C07D201/00 , C07F9/58 , C07F
Abstract: The present invention discloses 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium hemipentahydrate and monohydrate, methods of preparing the hemipentahydrate or monohydrate through control of the nucleation temperature and rate of crystallization and pharmaceutical compositions containing one or both of the hydrate forms.
-
公开(公告)号:PE00082003A1
公开(公告)日:2003-01-22
申请号:PE0003602002
申请日:2002-04-30
Applicant: SQUIBB BRISTOL MYERS CO
Inventor: DODD JOHN H , WATSON ANDREW J , PITTS WILLIAN JOHN
IPC: C07D239/95 , A61K31/00 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/5377 , A61K31/551 , A61K31/56 , A61K31/573 , A61K45/00 , A61P1/00 , A61P1/04 , A61P3/10 , A61P5/14 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/04 , A61P11/06 , A61P17/04 , A61P17/06 , A61P17/14 , A61P19/00 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07D201/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/16 , C07D487/04 , C07D491/10 , C07D498/10
CPC classification number: C07D403/12 , A61K31/00 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/522 , C07D401/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/00 , C07D473/16 , C07D487/04 , C07D491/10
Abstract: SE REFIERE A UN METODO PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA ACTIVACION DEL LEUCOCITO QUE COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE AL MENOS UN INHIBIDOR DUAL DE FOSFODIESTERASA 7 Y FOSFODIESTERASA 4 ( PDE7-PDE4) , PARA EL CUAL EL IC50 EN AMBOS ENSAYOS DE INHIBICION DE PDE7 Y PDE4 ES MENOS A 20 MICROMOLARES Y EL IC50 EN UN ENSAYO DE INHIBICION PDE3 ES AL MENOS 10 VECES MAYOR QUE EL IC50 DEL COMPUESTO EN EL ENSAYO PDE7. SON COMPUESTOS PREFERIDOS ETIL ESTER DEL ACIDO 4-METIL-2-[[6-(METILAMINO)-9-[[4-(METILSULFONIL)FENIL]METIL]-9H-PURIN-2-IL]AMINO]-5-TIAZOLCARBOXILICO, ETIL ESTER DEL ACIDO 4-METIL-2-[[9-[[4-(METILSULFONIL)FENIL]METIL]-6-[[[4-(METILSULFONIL)FENIL]METIL]AMINO]-9H-PURIN-2-IL]AMINO]-5-TIAZOLCARBOXILICO, ENTRE OTROS. LOS INHIBIDORES DUALES DE PDE7 Y PDE4 SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LA ACTIVACION DEL LEUCOCITO COMO ARTRITIS REUMATOIDE, PSORIASIS, ASMA
-
公开(公告)号:PE20011061A1
公开(公告)日:2001-11-20
申请号:PE2001000096
申请日:2001-01-29
Applicant: PROCTER & GAMBLE
Inventor: BILLINGS DENNIS MICHAEL , REDMAN-FUREY NANCY LEE , PARRY GREGORY EUGENE , CAZER FREDERICK DANA
IPC: A61K31/663 , A61K31/662 , A61K31/675 , A61P3/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P29/00 , C07D201/00 , C07F9/38 , C07F9/58
Abstract: SE REFIERE A UN PROCEDIMIENTO PARA FABRICAR HEMIPENTAHIDRATO Y MONOHIDRATO DE ACIDO 3-PIRIDIL-1-HIDROXI-ETILIDEN-1,1-BISFOSFONICO SODICO DE FORMULA I (RISEDRONATO) QUE COMPRENDE: a) PROVEER UNA SOLUCION ACUOSA DE ACIDO-PIRIDIL-1-HIDROXI- ETILIDEN-1,1-BISFOSFONICO SODIO; b) CALENTAR LA SOLUCION ACUOSA A UNA TEMPERATURA DE 45°C A 75°C APROXIMADAMENTE; c) ANADIR UN DISOLVENTE A LA SOLUCION ACUSA TAL COMO ALCOHOL, ESTER, ETER, ENTRE OTROS DE PREFERENCIA ISOPROPANOL; d) ENFRIAR OPCIONALMENTE LA SOLUCION ACUOSA A UNA VELOCIDAD DE 0,1°C A 5°C POR MINUTO. LA SOLUCION ACUOSA SE MANTIENE A 60°C DURANTE 4 HORAS Y LUEGO SE ENFRIA A 25 °C DURANTE DOS HORAS APROXIMADAMENTE. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 50% A 100% DE HEMIPENTAHIDRATO ACIDO 3-PIRIDIL-1-HIDROXI-ETILIDEN -1,1-BISFOSFONICO Y DE 0% A 50% DE MONOHIDRATO
-
公开(公告)号:BG103281A
公开(公告)日:2000-11-30
申请号:BG10328199
申请日:1999-03-25
Applicant: BALKANFARMA DUPNITSA AD
Inventor: PETKOV VLADIMIR J , STANEV STANCHO R , MILENKOV STRASHIMIR V , BOJCHEVA SNEZHANA A , NIKOLOVA EVELINA B , ANTOV VALERI D , KARKOVA AGNESA M , DEKOV NIKOLA G , RADEVA DIANA S , VELEVA JULIJA TS , JORDANOVA ADRIANA K , BASHIKAROVA ANTOANETA K , KONSTANTINOVA RUMJANA G , ELENSKA MAJA I , MITSEV GEORGI K , PEJCHEVA NATALIJA D , DIMANOVA RADOST G
IPC: C07D201/00 , C07D215/10
Abstract: The method has greater efficacy. By it a product is turned out of high yield and purity, particularly suitable for the preparation of inoculation forms. The method consists of reductive aminoethylation of aqueous solution of glucose and excess of aqueous solution of ethylamine with hydrogen at pressure ranging from 30 to 15 at. and temperature range of 40 to 50 deg. C in the presence of skeleton nickel catalyst. After the closure of the process the catalyst is separated from the reaction mixture which is treated with activated carbon at temperatures from 50 to 55 deg. C and is flitered. Immediately after that the reaction aqueous mixture is subjected to crystallization in stages being initially cooled down to 25-30 deg. C with agitation for about 2 to 5 h, after which the temperature is reduced to 0-2 deg. C and the mixture rests with no agitation for 1-2 h under these conditions. The N-ethylglucamine cristallizes with a high yield and purity. 1 claims
-
-
-
-
-
-
-
-
-